CannEpil® Shows Promising Results In Treatment-Resistant Epilepsy, According To Newly Published Peer-Reviewed Case Study

Argent BioPharma Limited has announced the publication of a new independent, peer-reviewed case study highlighting the therapeutic potential of its proprietary formulation, CannEpil®, in the treatment of drug-resistant epilepsy. The study appears in the International Journal of Clinical Medicine & Case Reports under the title “Management of Lennox-Gastaut Syndrome with a CBD/THC Isolate Combination” (DOI: 10.46998/IJCMCR.2025.54.001331).

The case study focuses on the treatment of a pediatric patient with Lennox-Gastaut Syndrome, a severe and difficult-to-treat form of epilepsy. The patient was administered CannEpil®, a pharmaceutical-grade CBD/THC isolate formulation developed by Argent BioPharma under EU-GMP manufacturing standards.

Authored by Dr. Jonathan Grunfeld, Vice President of Medical Development at Argent BioPharma, and medical researcher Dr. Jasna Jarc, the report outlines significant clinical improvements observed during treatment. These included a noticeable reduction in seizure clusters and overall seizure frequency, as well as recovery of speech, fine motor control, and independent mobility. The patient was also able to return to a full-time educational setting, an important indicator of improved quality of life.

Dr. Jonathan Grunfeld, VP of Medical Development at Argent BioPharma, stated, "This case exemplifies the transformative impact a rigorously formulated cannabinoid therapy can have on patients for whom standard treatments have failed. CannEpil®’s precision, purity, and clinical consistency are central to its success.”

The publication adds to the expanding real-world evidence supporting CannEpil® for the management of complex epilepsy syndromes. It also highlights the advantages of pharmaceutical-grade isolate formulations, such as improved dosing accuracy and enhanced safety, compared to full-spectrum botanical alternatives.